AV-GBM-1 Patient-Specific Vaccines in Newly Diagnosed Primary Glioblastoma

Time: 4:45 pm

Details:

• AV-GBM-1 product and manufacturing feasibility update
• Phase 2 safety and survival data including exploratory subset analyses
• Phase 3 clinical trial considerations and design